Increase awareness about colorectal cancer to promote early diagnosis and treatment, reducing mortality rates worldwide.

ST316, a β-catenin/BCL9 antagonist, demonstrated safety, target engagement, and early antitumor activity in advanced solid tumors.

According to the World Health Organization (WHO), colorectal cancer is the third most common cancer worldwide, accounting for ...